Landiolol decreases a dysrhythmogenic dose of epinephrine in dogs during halothane anesthesia.
OBJECTIVE
To examine the effect of landiolol (ONO-1101), a new ultra-short acting and highly selective beta blocker, on epinephrine-induced ventricular arrhythmias in halothane-anesthetized dogs.


METHODS
We administered five different doses (0, 0.1, 0.5, 1.0, 10 microg x kg(-1) x min(-1)) landiolol and determined the dysrhythmogenic dose of epinephrine (DDE), defined as the smallest dose producing four or more PVCs within 15 sec, at each dose of landiolol and after cessation of infusion.


RESULTS
The control value of DDE during 1.3 MAC halothane anesthesia was 1.26 +/- 0.44 (mean +/- SD) microg x kg(-1) x min(-1) and the corresponding plasma concentration of epinephrine (PCE) was 12.2 +/- 8.3 ng x ml(-1). Concomitant administration of 10 microg x kg(-1) x min(-1) landiolol increased DDE and corresponding PCE (P < 0.05). At 30 min after cessation of landiolol infusion, DDE and corresponding PCE returned to the control values.


CONCLUSIONS
Landiolol, at a dose of 10 microg x kg(-1) x min(-1), has an antiarrhythmic effect on epinephrine-induced ventricular arrhythmias in dogs during anesthesia with halothane.
Takahashi
S
S
Department of Anaesthesiology, University of Tsukuba, Institute of Clinical Medicine, Ibaraki, Japan. shinjitk@db3.so-net.ne.jp
Fujii
Y
Y
Inomata
S
S
Miyabe
M
M
Toyooka
H
H
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D018685:Anesthetics, Inhalation / Q000008:administration & dosage*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004285:Dogs; D004347:Drug Interactions; D004837:Epinephrine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D005260:Female; D006221:Halothane / Q000008:administration & dosage*; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018879:Ventricular Premature Complexes / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018685:Anesthetics, Inhalation; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea; D006221:Halothane; D004837:Epinephrine